炎症性肠病年轻患者接受免疫调节治疗增加非黑色素瘤皮肤癌风险
结果显示,使用免疫调节剂患者的标准化发病比为1.8(95%CI: 1.0-2.7),硫嘌呤暴露(OR: 5.26, 95%CI: 2.15-12.93, P<0.001)及硫嘌呤和/或TNF-α抑制剂暴露(OR: 6.45, 95%CI: 2.69-15.95, P<0.001)与NMSC显著相关。
要点
- IBD患者使用免疫调节剂时NMSC标准化发病比为1.8(95%CI: 1.0-2.7)。
- 硫嘌呤暴露与NMSC风险显著相关(OR: 5.26, 95%CI: 2.15-12.93)。
- 硫嘌呤和/或TNF-α抑制剂暴露风险更高(OR: 6.45, 95%CI: 2.69-15.95)。
核心结论
- 使用免疫调节剂的IBD患者非黑色素瘤皮肤癌风险增加,尤其与硫嘌呤及TNF-α抑制剂暴露相关。
- 应强调所有IBD患者遵守皮肤癌预防措施,对免疫抑制患者特别是年轻时即暴露于双免疫调节剂者降低皮肤科转诊门槛。
研究设计与样本
- 将皮肤癌发病率与爱尔兰国家癌症登记处人群数据比较,计算标准化发病比,并采用逻辑回归分析危险因素。
主要发现
- 使用免疫调节剂的IBD患者NMSC总体标准化发病比为1.8(95%CI: 1.0-2.7),某些年龄别发病率显著升高。
- 硫嘌呤暴露与NMSC显著相关(OR: 5.26, 95%CI: 2.15-12.93, P<0.001)。
- 硫嘌呤和/或TNF-α抑制剂暴露与NMSC显著相关(OR: 6.45, 95%CI: 2.69-15.95, P<0.001)。
- 暴露于TNF-α抑制剂的患者中82%同时有硫嘌呤暴露。
临床怎么用
- 对IBD患者应强调皮肤癌预防措施,包括防晒和皮肤监测。
- 对免疫抑制的IBD患者,尤其年轻时即暴露于双免疫调节剂者,应降低皮肤科转诊门槛。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent studies report an increased risk of non-melanoma skin cancer (NMSC) in immunosuppressed patients with inflammatory bowel disease (IBD). Concurrently, paediatric IBD incidence is rising, with more patients now exposed to immunomodulators from a younger age. OBJECTIVES: To investigate NMSC incidence and to examine the risk associated with immunomodulators in the development of NMSC in patients with IBD. METHODS: This was a retrospective single-centre cohort study. Patients with IBD attending a tertiary adult hospital from 1994 to 2013 were included. Skin cancer incidence was compared with population data from the National Cancer Registry of Ireland (NCRI) to calculate standardized incidence ratio (SIR). Logistic regression was utilized for risk factor analysis. RESULTS: Two thousand and fifty-three patients with IBD were studied. The SIR for NMSC in patients with IBD taking immunomodulators overall was 1.8 (95% CI: 1.0-2.7) with age-specific rates significantly elevated across certain age categories. Exposure to thiopurines (OR: 5.26, 95% CI: 2.15-12.93, P < 0.001) and in particular thiopurines and/or tumour necrosis factor alpha (TNF-α) inhibitors (OR: 6.45, 95% CI: 2.69-15.95, P < 0.001) was significantly associated with NMSC. The majority (82%) of those exposed to a TNF-α inhibitor also had thiopurine exposure. CONCLUSIONS: Compliance with skin cancer preventative measures should be highlighted to all patients with IBD. There should be a low threshold for dermatology referral for immunosuppressed patients, particularly those with a history of exposure to dual immunomodulators from a young age.
引用
- Clowry J, Sheridan J, Healy R, et al. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study. J Eur Acad Dermatol Venereol. 2017. PMID: 28045204. doi:10.1111/jdv.14105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。